Clinical Trial Update: Estrogen Receptor Variants, HDL, and Atherosclerosis

View source ↗

Summary

A completed NHLBI clinical trial update examining the relationship between estrogen receptor variants, HDL levels, and atherosclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Coronary Artery Disease
• Heart Disease

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Atherosclerosis | Status: COMPLETED